Posted by Michael Wonder on 27 Feb 2018
Health Canada has approved Fasenra (benralizumab injection) for patients with severe eosinophilic asthma
26 February 2018 - AstraZeneca Canada today announced that Health Canada has approved Fasenra (benralizumab injection) as an add-on maintenance treatment for adult patients with severe eosinophilic asthma.
The Health Canada approval is based on results from the WINDWARD clinical program, including the pivotal Phase III exacerbation trials.
